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et al., 1983). A recent claims-based
study from Detroit, Michigan, found
that warts were more commonly
diagnosed in Caucasians (22.6%) than
in African Americans (5.7%) (Henderson
et al., 2012). A previous study of the
determinants of sexually transmitted
infections found that Caucasians were
more likely than African Americans to
have venereal warts (Short et al., 1984).
Furthermore, a recent prevalence study
of warts in Caucasian Dutch
schoolchildren aged 4–12 years showed
that one-third of the children had warts
(van Haalen et al., 2009). This suggests
that the incidence described in the
United States may actually be lower
than that in other countries owing to
the mixture of racial and ethnic groups
in our population.
The strengths of this study include
being a large-scale, US population–
based survey with minimal selection
bias, and controlling for confounding
demographic variables in multivariate
models. However, the study also has
some limitations. Warts and comorbid-
ities were assessed by caregiver report,
which have not been fully validated.
The appearance of common warts is
reasonably characteristic, and lay recog-
nition can be assumed to be good.
Another concern about self/parental-
reported warts is potential reporting
bias, where subjects with higher socio-
economic status may have better overall
health and be more motivated to seek
out care for warts. Future studies are
needed to validate the accuracy of self/
caregiver report and determine the ideal
survey instrument for the epidemiologic
study of these disorders.
The peak age of warts occurring at
9–10 years and common presence in
teenagers may relate to school atten-
dance and exposures from peer groups.
School- and family-based transmissions
have been cited as a leading cause of
disease (van Haalen et al., 2009). Age-
specific physical activity and sports
participation, particularly swimming
pool use (Penso-Assathiany et al.,
1999) and use of communal showers
(Johnson, 1995), have been linked to
transmission of warts. Racial/ethnic and
socioeconomic disparities may affect
age-specific activities and pool use.
Future studies are warranted to deter-
mine the role of age-specific physical
activities and local environment on the
US prevalence of warts.
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TO THE EDITOR
Rosacea is a chronic facial skin disease
with a presumed key vasodilatory
component (Steinhoff et al., 2011),
whereas diabetes mellitus (DM) is
associated with impaired vasodilation
congruent with the degree of
endothelial dysfunction. Insulin is a
physiologic regulator of the vascular
tone, but in the insulin-resistant state
insulin increases vasoconstriction
(Browne et al., 2003; Kim et al., 2006;
Rask-Madsen and King, 2007; Cade,
2008; Barrett et al., 2009; Ko et al.,
2010). Using the UK-based GeneralAccepted article preview online 8 May 2013; published online 27 June 2013
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DM, diabetes mellitus; GPRD, General Practice Research Database; HbA1c , hemoglobin A1c ; ISAC,
Independent Scientific Advisory Committee; MHRA, Medicines and Healthcare Products Regulatory
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Practice Research Database (GPRD;
Khan et al., 2010), we conducted a
large population-based case–control
analysis, including patients with a
first-time rosacea diagnosis (index date)
between January 1995 and September
2009. We excluded patients with
recorded alcoholism (explicit medical
Read-code), cancer, or HIV, and
patients with o3 years of recorded
active history before the index date.
Patients with diagnosed rhinophyma or
ocular rosacea in the absence of another
record of facial rosacea were excluded.
We randomly matched one control to
each case on age, sex, general practice,
calendar time, and number of previous
years of history in the database, and
applied the same exclusion criteria to
controls as to cases. The study protocol
was approved by the ISAC (Independent
Scientific Advisory Committee) for
MHRA (Medicines and Healthcare
Products Regulatory Agency) database
research. Disease exposure was defined
as a DM diagnosis (validity proven
elsewhere; Khan et al., 2010; Van Staa
and Abenhaim, 1994) before the index
date. Among DM patients, we captured
the last hemoglobin A1c (HbA1c) value
before the index date, stratified into four
categories (none, p7.5%, 7.6–10.9%,
or X11%). DM duration was stratified
into six categories by the number of
years between the first recorded
prescription of any antidiabetic drug
and the index date (no treatment, o1,
1–3, 3–5, 5–10, and 10þ years), sub-
stratified by HbA1c levels (p7.5% or
47.5%). We analyzed antidiabetic drug
use (insulin vs. other antidiabetic drugs)
stratified by timing (p or 4180 days
before the index date) and duration of
use (number of prescriptions before the
index date). Within a mutually exclusive
drug use model among diagnosed
diabetics, we assessed insulin exposure
(irrespective of any oral antidiabetic
drug (OAD) use) and OAD exposure
alone (no insulin exposure at any time),
stratified by timing and duration of
drug use and by HbA1c levels. We
conducted multivariate conditional
logistic regression analyses using SAS
statistical software (version 9.3, SAS
Institute, Cary, NC), and calculated odds
ratios (ORs) with 95% confidence
intervals (CIs). We adjusted all ORs for
smoking (non, current, ex, unknown),
alcohol consumption (0, 1–4, 5–9,
10–14, 15–24, or 25þ units per week,
unknown), and body mass index
(BMI, o18.5, 18.5–24.9, 25.0–29.9, or
þ 30 kg m2, unknown). Because other
potential confounders, i.e., depression,
cardiovascular diseases (hypertension,
myocardial infarction, hyperlipidemia,
heart failure, ischemic heart disease,
ischemic stroke/transient ischemic
attack), cardiovascular drugs (calcium
channel blockers, b-blockers, angioten-
sin-converting enzyme (ACE) inhibitors,
angiotensin receptor blockers, statins,
acetylsalicylic acid (anticlotting dosage),
vitamin K antagonists, and diuretics),
systemic steroids, and nonsteroidal
anti-inflammatory drugs (NSAIDs) did
not alter the relative risk estimates
for the association between DM
or insulin and rosacea by X10%,
we did not include them in the final
model.
The study population’s demographics
and methodology including limitations
have been described in detail elsewhere
(Spoendlin et al., 2012). Of the 53,927
rosacea cases and the same number of
controls, 1,686 (3.1%) cases and 2,042
(3.8%) controls had a recorded
DM diagnosis revealing an OR of 0.80
(95% CI 0.74–0.85), which further
decreased with increasing HbA1c
values (OR 0.57, 95% CI 0.41–0.79,
Table 1. Distribution of diagnosed DM stratified by HbA1c values and disease duration
Rosacea cases,
no. (n¼ 53,927) (%)1
Rosacea-free controls,
no. (n¼53,927) (%)1 OR crude (95% CI) OR adj2 (95% CI)
No diagnosed DM1 52,241 (96.9) 51,885 (96.2) 1.00 (ref.) 1.00 (ref.)
Diagnosed DM 1,686 (3.1) 2,042 (3.8) 0.81 (0.76–0.87) 0.80 (0.74–0.85)
Diagnosed DM by HbA1c (%)
0–7.5 880 (1.6) 971 (1.8) 0.89 (0.81–0.98) 0.87 (0.79–0.96)
7.6–10.9 519 (1.0) 684 (1.3) 0.75 (0.67–0.84) 0.73 (0.65–0.82)
X11 58 (0.1) 101 (0.2) 0.57 (0.41–0.78) 0.57 (0.41–0.79)
NA 229 (0.4) 286 (0.5) 0.79 (0.66–0.94) 0.78 (0.65–0.94)
Diagnosed DM by treatment duration (years)
Untreated 444 (0.8) 439 (0.8) 1.00 (0.87–1.14) 0.96 (0.84–1.10)
o1 135 (0.3) 170 (0.3) 0.79 (0.63–0.99) 0.78 (0.62–0.98)
1–3 288 (0.5) 325 (0.6) 0.87 (0.74–1.02) 0.85 (0.72–1.00)
3–5 252 (0.5) 312 (0.6) 0.79 (0.67–0.94) 0.80 (0.68–0.95)
5–10 368 (0.7) 503 (0.9) 0.72 (0.63–0.82) 0.71 (0.62–0.81)
X10 199 (0.4) 293 (0.5) 0.67 (0.55–0.80) 0.64 (0.54–0.78)
Abbreviations: adj, adjusted; CI, confidence interval; DM, diabetes mellitus; HbA1c, hemoglobin A1c; NA, no answer; OR, odds ratio; ref., reference.
1Percentages are rounded to nearest decimal.
2OR adjusted for smoking, body mass index, and alcohol consumption.
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HbA1c X11%) and with increasing
disease duration (OR 0.64, 95% CI
0.54–0.78, disease duration X10
years; Table 1). At earlier disease stages,
we observed decreased ORs in poorly
controlled diabetics (HbA1c 47.5%),
whereas a disease history of X5 years
revealed decreased ORs irrespective of
blood glucose control (Supplementary
Table S2 online). Exposure to any anti-
diabetic drug was associated with a
decreased OR of 0.76 (95% CI 0.71–
0.83). The prevalence of insulin expo-
sure was higher in controls (1.1%) than
in cases (0.7%), yielding an OR of 0.75
(95% OR 0.65–0.85), unchanged across
strata of timing and duration of insulin
exposure. OAD exposure was also
slightly more prevalent in controls
(2.6%) than in cases (2.1%, OR 0.83,
95% CI 0.76–0.91), again independent
of timing and duration of drug exposure
(Supplementary Table S1 online). The
mutually exclusive drug use model
(Table 2) yielded significantly decreased
ORs for insulin users, irrespective of
HbA1c control. OAD use in the absence
of insulin was associated with decreased
ORs at HbA1c levels 47.5%, but non-
significant results at HbA1c levels
p7.5%.
Our findings suggest a decreased
rosacea risk in DM patients at an
advanced disease state, i.e., in patients
with high HbA1c levels and/or long
disease duration. The underlying
mechanism remains to be clarified; we
hypothesize a reciprocal link of the two
diseases via the degree of endothelial
dysfunction and thus impaired vasodila-
tion. Extrinsic insulin exposure revealed
significantly decreased ORs, irrespective
of HbA1c control, whereas OAD use
yielded decreased ORs in poorly
controlled diabetics only. This might
reflect an additional insulin effect on
the rosacea risk, but it could also depict
a proxy for disease duration and/or
severity. As insulin is used in diabetic
patients only, we cannot disentangle the
role of insulin from the underlying
disease within this observational study.
Most diabetic patients were coded with
a DM subtype–unspecific code (66.6%
cases, 68.3% controls), but as ORs
were decreased in insulin users and in
poorly controlled OAD users, a sub-
type-independent effect seems likely,
especially as endothelial damage and
diabetic microvascular complications
are presumably driven by shared
mechanisms caused by hyperglycemia
in both DM subtypes (The Diabetes
Control and Complications Trial
Research Group, 1993; UKPDS Group,
1998; Browne et al., 2003; Schalkwijk
and Stehouwer, 2005; Rask-Madsen and
King, 2007; Cade, 2008). Our study
provides evidence for a significantly
Table 2. Mutually exclusive antidiabetic drug use stratified by timing and duration of drug exposure and by HbA1c
values
Rosacea cases,
no. (n¼53,927) (%)1
Rosacea-free controls,
no. (n¼ 53,927) (%)1 OR crude (95% CI) OR adj2 (95% CI)
No DM 52,241 (96.9) 51,885 (96.2) 1.00 (ref.) 1.00 (ref.)
Diagnosed DM untreated 444 (0.8) 439 (0.8) 1.00 (0.88–1.14) 0.96 (0.84–1.10)
Diagnosed DM, HbA1cp7.5
Current insulin 1–39 (±OAD3) 52 (0.1) 73 (0.1) 0.70 (0.49–1.00) 0.67 (0.47–0.96)
Current insulin 40þ (±OAD3) 37 (0.1) 54 (0.1) 0.68 (0.44–1.03) 0.69 (0.45–1.05)
Past insulin use (±OAD3) 9 (0.0) 16 (0.0) 0.56 (0.25–1.27) 0.55 (0.24–1.24)
Current OAD3 only, 1–19 154 (0.3) 175 (0.3) 0.87 (0.70–1.08) 0.84 (0.67–1.04)
Current OAD only, 20–39 125 (0.2) 143 (0.3) 0.86 (0.67–1.10) 0.85 (0.67–1.09)
Current OAD only, 40þ 184 (0.3) 195 (0.4) 0.92 (0.75–1.13) 0.92 (0.75–1.13)
Past OAD use only 20 (0.0) 32 (0.1) 0.59 (0.34–1.04) 0.62 (0.35–1.09)
Diagnosed DM, HbA1c47.5
Current insulin 1–39(±OAD3) 118 (0.2) 160 (0.3) 0.72 (0.57–0.92) 0.72 (0.57–0.92)
Current insulin 40þ (±OAD3) 119 (0.2) 160 (0.3) 0.73 (0.58–0.93) 0.69 (0.55–0.88)
Past insulin use (±OAD3) 7 (0.0) 14 (0.0) 0.48 (0.20–1.20) 0.43 (0.17–1.07)
Current OAD3 only, 1–19 103 (0.2) 138 (0.3) 0.74 (0.57–0.95) 0.72 (0.55–0.93)
Current OAD only, 20–39 76 (0.1) 83 (0.2) 0.91 (0.66–1.24) 0.90 (0.65–1.23)
Current OAD only, 40þ 118 (0.2) 159 (0.3) 0.73 (0.58–0.93) 0.73 (0.57–0.92)
Past OAD use only 3 (0.0) 29 (0.1) 0.10 (0.03–0.33) 0.11 (0.03–0.36)
Treated DM, HbA1c not recorded 117 (0.2) 172 (0.3) 0.67 (0.53–0.85) 0.67 (0.52–0.85)
Abbreviations: CI, confidence interval; DM, diabetes mellitus; HbA1c, hemoglobin A1c; OAD, oral antidiabetic drug; OR, odds ratio; ref., reference.
1Percentages are rounded to the nearest decimal.
2Adjusted for smoking, body mass index, and alcohol consumption.
3OADs include biguanides, sulfonylureas, thiazolidinediones, glinides, a-glucosidase inhibitors, and incretin-mimetics.
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reduced rosacea risk in diabetics at an
advanced disease stage. This is, to our
knowledge, a previously unreported
finding, but some residual confounding
or chance cannot entirely be
ruled out. Whether insulin enhances
this effect per se or whether it reflects
a proxy for disease severity remains
unclear.
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A Mutation-Independent Therapeutic Strategy for
Dominant Dystrophic Epidermolysis Bullosa
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TO THE EDITOR
Dominant dystrophic epidermolysis
bullosa (DDEB) is a rare genetic blistering
skin disorder with no known cure. The
disorder is caused by mutations in the
COL7A1 gene leading to weakened
a1(VII) (collagen VII) homotrimers,
whose function is to knit epidermal
and dermal skin layers together
(Parente et al., 1991; McGrath et al.,
1993). Over 60 COL7A1 mutations
have been implicated in DDEB,
making this disorder, similar to
many other dominant disorders,
extremely heterogenous (Nakamura
et al., 2004).
A gene therapy strategy for DDEB
involving suppression of mutant
COL7A1 transcripts using allele-specific
RNA interference (RNAi) molecules tar-
geting a mutation site has been adopted
in vitro (Pendaries et al., 2012). This
informative study demonstrated potent
and specific RNAi-mediated allele-
specific suppression of a COL7A1
splice-site mutation in cells; similar
levels of RNAi specificity have been
obtained by others (Hickerson et al.,
2008; Lindahl et al., 2008; Atkinson
et al., 2011). In contrast, for many
COL7A1 mutations and indeed other
target genes, allele-specific RNAi
suppression has not been achieved (de
Yn˜igo-Mojado et al., 2011; Pendaries
et al., 2012 and Morgan et al.,
unpublished data).
Given the vast array of COL7A1
mutations implicated in DDEB, the
development of RNAi-mediated mutation-
specific therapies targeting each mutant
is not technically/economically feasible.
In this study, we have addressed the
substantial problem of DDEB-associated
mutational heterogeneity and have
tested four mutation-independent small
interfering RNAs (siRNAs; si1-si4) tar-
geting different regions of the COL7A1Accepted article preview online 6 June 2013; published online 11 July 2013
Abbreviations: DDEB, dominant dystrophic epidermolysis bullosa; NT, nontargeting negative control
RNAi; R, replacement COL7A1 gene; RNAi, RNA interference; siRNA, small interfering RNA
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